Noah Clauser - 21 Mar 2025 Form 4 Insider Report for Astria Therapeutics, Inc. (ATXS)

Role
Chief Financial Officer
Signature
/s/ Ben Harshbarger, as attorney-in-fact for Noah Clauser
Issuer symbol
ATXS
Transactions as of
21 Mar 2025
Net transactions value
$0
Form type
4
Filing time
25 Mar 2025, 16:05:43 UTC
Previous filing
12 Feb 2024
Next filing
23 Jan 2026
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATXS Stock Option (Right to Buy) Award $0 +262,500 $0.000000 262,500 21 Mar 2025 Common Stock 262,500 $6.41 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on March 21, 2025 and is subject to vesting over a four-year period, with 25% of the 262,500 shares underlying the option upon grant vesting on the first anniversary of February 13, 2025 and the remainder vesting over the ensuing three years in equal monthly installments.